Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2007 1
2008 2
2009 1
2010 9
2011 10
2012 8
2013 19
2014 22
2015 25
2016 19
2017 8
2018 21
2019 12
2020 41
2021 48
2022 41
2023 25
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

276 results

Results by year

Filters applied: . Clear all
Page 1
Siltuximab.
[No authors listed] [No authors listed] 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999789 Free Books & Documents. Review.
No information is available on the clinical use of siltuximab during breastfeeding. Because siltuximab is a large protein molecule with a molecular weight of about 145,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroye …
No information is available on the clinical use of siltuximab during breastfeeding. Because siltuximab is a large protein mole …
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C. van Rhee F, et al. Lancet Oncol. 2014 Aug;15(9):966-74. doi: 10.1016/S1470-2045(14)70319-5. Epub 2014 Jul 17. Lancet Oncol. 2014. PMID: 25042199 Clinical Trial.
FINDINGS: We screened 140 patients, 79 of whom were randomly assigned to siltuximab (n=53) or placebo (n=26). Durable tumour and symptomatic responses occurred in 18 (34%) of 53 patients in the siltuximab group and none of 26 in the placebo group (difference 34.0%, …
FINDINGS: We screened 140 patients, 79 of whom were randomly assigned to siltuximab (n=53) or placebo (n=26). Durable tumour and symp …
Siltuximab.
[No authors listed] [No authors listed] 2016 Apr 9. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2016 Apr 9. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644237 Free Books & Documents. Review.
Siltuximab is a chimeric human-mouse monoclonal antibody to interleukin-6 which is used in the therapy of Castleman disease. Siltuximab commonly causes mild serum aminotransferase elevations which are usually short lived and asymptomatic, but it has not been linked …
Siltuximab is a chimeric human-mouse monoclonal antibody to interleukin-6 which is used in the therapy of Castleman disease. Siltu …
Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.
van Rhee F, Rosenthal A, Kanhai K, Martin R, Nishimura K, Hoering A, Fajgenbaum DC. van Rhee F, et al. Blood Adv. 2022 Aug 23;6(16):4773-4781. doi: 10.1182/bloodadvances.2022007112. Blood Adv. 2022. PMID: 35793409 Free PMC article. Clinical Trial.
We performed post hoc analyses of the phase 2 randomized double-blind placebo-controlled trial of siltuximab for the treatment of patients with iMCD to determine the sequence of normalization of laboratory, clinical, and lymph node responses in patients who responded to …
We performed post hoc analyses of the phase 2 randomized double-blind placebo-controlled trial of siltuximab for the treatment of pat …
Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.
Lyseng-Williamson KA. Lyseng-Williamson KA. BioDrugs. 2015 Dec;29(6):399-406. doi: 10.1007/s40259-015-0142-5. BioDrugs. 2015. PMID: 26394632 Review.
In clinical trials in patients with iMCD, siltuximab reduced levels of C-reactive protein (a biomarker for IL-6), and provided clinical responses. ...In the absence of a cure, siltuximab represents a significant achievement in the management of this difficult-to-tre …
In clinical trials in patients with iMCD, siltuximab reduced levels of C-reactive protein (a biomarker for IL-6), and provided clinic …
Siltuximab: first global approval.
Markham A, Patel T. Markham A, et al. Drugs. 2014 Jul;74(10):1147-52. doi: 10.1007/s40265-014-0249-x. Drugs. 2014. PMID: 24958337 Review.
The anti-interleukin-6 (IL-6) chimeric monoclonal antibody siltuximab is the first drug to be approved for the treatment of multicentric Castleman's disease (MCD) in the US and European union (EU), having gained approval under the FDA priority review program in the US and …
The anti-interleukin-6 (IL-6) chimeric monoclonal antibody siltuximab is the first drug to be approved for the treatment of multicent …
Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.
Ferrario A, Merli M, Basilico C, Maffioli M, Passamonti F. Ferrario A, et al. Expert Opin Investig Drugs. 2017 Mar;26(3):367-373. doi: 10.1080/13543784.2017.1288213. Epub 2017 Feb 9. Expert Opin Investig Drugs. 2017. PMID: 28140696 Review.
Areas covered: This review discusses available data related to the role of IL-6 as a therapeutic target, the characteristics of Siltuximab in term pharmacokinetics and pharmacodynamics properties and a detailed analysis of the studies involving haematological malignancies …
Areas covered: This review discusses available data related to the role of IL-6 as a therapeutic target, the characteristics of Siltuxima …
Clinical development of siltuximab.
Davis CC, Shah KS, Lechowicz MJ. Davis CC, et al. Curr Oncol Rep. 2015 Jul;17(7):29. doi: 10.1007/s11912-015-0453-1. Curr Oncol Rep. 2015. PMID: 25986720 Review.
Siltuximab treatment therefore is important in the overall treatment of this rare disease state. This review focuses on the clinical development and pharmaceutical approval of siltuximab....
Siltuximab treatment therefore is important in the overall treatment of this rare disease state. This review focuses on the clinical …
Impact of siltuximab on patient-related outcomes in multicentric Castleman's disease.
Sitenga J, Aird G, Ahmed A, Silberstein PT. Sitenga J, et al. Patient Relat Outcome Meas. 2018 Jan 12;9:35-41. doi: 10.2147/PROM.S140011. eCollection 2018. Patient Relat Outcome Meas. 2018. PMID: 29391839 Free PMC article. Review.
Clinical trials with siltuximab have shown early clinical promise for patients with MCD for many years, leading to recent US Food and Drug Administration approval as a novel agent for the treatment of MCD. Here, a systematic review was conducted to include 171 cases of MCD …
Clinical trials with siltuximab have shown early clinical promise for patients with MCD for many years, leading to recent US Food and …
Siltuximab Monotherapy in Tafro Syndrome: A Case Report and Review of the Literature.
Cordero L, Aguilar-Rodríguez F, Sandino J, Alonso M, Gutiérrez E. Cordero L, et al. J Nephrol. 2023 May;36(4):1181-1185. doi: 10.1007/s40620-022-01517-4. Epub 2023 Jan 18. J Nephrol. 2023. PMID: 36652167 Review.
The patient was diagnosed with TAFRO syndrome and treatment with siltuximab was started, with evident improvement at 3 months. TAFRO syndrome is a rare entity which may present with severe kidney involvement and histological findings of MPGN or TMA, with or without immune …
The patient was diagnosed with TAFRO syndrome and treatment with siltuximab was started, with evident improvement at 3 months. TAFRO …
276 results

Searches related to "siltuximab"